Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2018
Reporting Period: Specific event date of May 28, 2018.
Event Summary
On May 28, 2018, the company submitted its day-181 responses to the European Medicines Agency (EMA) regarding day-180 questions related to CHS-1701, its pegfilgrastim (Neulasta®) biosimilar candidate market authorization application in Europe.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a regulatory milestone and does not contain financial statements.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document reports a procedural update in the regulatory approval process for a specific drug candidate.
Outlook, Risks, and Management Commentary
- Regulatory Progress: The submission of responses to the EMA indicates continued engagement in the approval process for CHS-1701 in Europe.
- Risks and Contingencies: The filing does not explicitly detail new risks, though the outcome of the EMA review remains a contingency for the commercialization of the biosimilar candidate.
- Unusual Items: None reported.
Key Facts for Investor Verification
- Verify the status of the EMA review process following the May 28, 2018 submission.
- Confirm the timeline for any potential decision or further questions from the EMA regarding CHS-1701.
- Monitor subsequent filings for updates on the market authorization application in Europe.